

Grifols announces receipt of Required Consents and termination of revocation rights of the consented Holders in connection with the Consent Solicitation to amend the Indenture relating to its outstanding €1,300,000,000 7.500% Senior Secured Notes due 2030

Barcelona, November 11, 2025. Grifols, S.A. (“Grifols” or the “Company”) announces that it has received the required consents in connection with its previously announced consent solicitation (the “Solicitation”) from holders of the Company’s €1,300,000,000 7.500% Senior Secured Notes due 2030 (ISIN XS2805351843 (Reg. S) and XS2805352064 (144A)) (the “Notes”) to amend certain provisions of the indenture dated April 30, 2024, as amended or supplemented (the “Indenture”) governing the Notes in order to, among other things, align certain provisions of the Notes and the Indenture with the terms and conditions of the Company’s more recently-issued 7.125% senior secured notes due 2030 and the indenture governing such notes (the “Proposed Amendments”).

As of 11:20 a.m. London time of the date hereof (the “Revocation Deadline”), the Company had received the Required Consents from the holders of the Notes to approve the Proposed Amendments described in the consent solicitation statement, dated as of November 4, 2025 (the “Consent Solicitation Statement”). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the Consent Solicitation Statement.

As a result of the receipt of the Required Consents, such consents are now irrevocable and may not be withdrawn or revoked by the Holders. Holders of Notes who validly delivered their consents are eligible to receive the Consent Payment with respect to their consented Notes. The Solicitation will remain open until 4:00 p.m. London time of November 12, 2025 (the “Expiration Time”), to allow additional holders of the Notes to deliver consents should they wish to do so.

Given the receipt of the Required Consents, Grifols will enter into a supplemental indenture in respect of the Indenture and the Notes incorporating the Proposed Amendments. The Proposed Amendments will become effective on the date of execution of the Supplemental Indenture (the “Effective Date”), but the Supplemental Indenture will provide that the Proposed Amendments will not become operative until the conditions precedent set forth in the Consent Solicitation Statement have been satisfied or waived, including the payment of the Consent Payment, in accordance with the terms of the Solicitation.

If the Proposed Amendments become operative, the Holders who did not consent to the Proposed Amendments on or prior to the Expiration Time, including any transferees of the Notes from such Holders, will still be bound by the Proposed Amendments and will not receive a Consent Payment.

Additional details regarding the Solicitation are described in the Consent Solicitation Statement. This announcement must be read in conjunction with the Consent Solicitation Statement.

Neither this announcement nor the Solicitation is an offer to sell the securities of the Company. No offering of securities was or will be made in connection with the Solicitation. The Consent Solicitation Statement does not constitute or contemplate an invitation to participate in the Solicitation in any jurisdiction in which, or to any person to whom, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. The distribution of the Consent Solicitation Statement in certain jurisdictions may be restricted by law. Persons into whose possession the Consent Solicitation Statement comes are required to inform themselves about, and to observe, any such restrictions. Nothing in the Consent Solicitation Statement constitutes or contemplates an invitation to participate in the Solicitation by a holder of the Notes in any circumstances in which such participation is unlawful.

INVESTORS:

Grifols Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACT:

Grifols Press Office

media@grifols.com

Tel.: +34 93 571 00 02

The Tabulation and Information Agent

Kroll Issuer Services Limited

E-mail: grifols@is.kroll.com

Website: <https://deals.is.kroll.com/grifols>

The Lead Solicitation Agent

BofA Securities Europe SA

Email: DG.LM-EMEA@bofa.com

The Consent Solicitation Agents

Banco Santander, S.A.

Email: LiabilityManagement@gruposantander.com

DNB Carnegie Investment Bank AB (publ)

Email: bond.syndicate@dnbcarnegie.no

J.P. Morgan SE

Email: liability_management_EMEA@jpmorgan.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group. Neither the Solicitation Agents nor the Tabulation and Information Agent have independently verified information in the Consent Solicitation Statement, and none of them makes any representation or warranty, express or implied, or assumes any responsibility as to, the accuracy or adequacy of the information contained herein, therein or in any document prepared in connection with the Solicitation. The Solicitation Agents are acting exclusively for the Company and no one else in connection with the Solicitation.



CCC B BB BBB A AA AAA